Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pathogenesis of Rett Syndrome: Natural History and Treatment
NCT00069550Phase 3
Key facts
- Status
- Unknown
- Start
- Sep 2004
- Countries
- 1
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- Modality
- Small Molecules
- Conditions
- Rett syndrome (RTT)
01
Overview
Phase 3, randomised trial of dextromethorphan and donepezil in Rett syndrome (RTT) (4 arms), sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development. Status: unknown.
02
Design
4 arms- Study design
- Randomized
Dextromethorphan Dose 1
Participants randomized to receive the first dose level of dextromethorphan.
Dextromethorphan Dose 2
Participants randomized to receive the second dose level of dextromethorphan.
Dextromethorphan Dose 3
Participants randomized to receive the third dose level of dextromethorphan.
Donepezil hydrochloride
Participants in the second part of the study receiving donepezil hydrochloride.
03
Who it enrols
Patients diagnosed with Rett syndrome who have a mutation in the MeCP2 gene and typical EEG abnormalities.
Beyond the preview
Go deeper on NCT00069550.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00069550.